CD8A and cancer: Repurposing denosumab in primary cancer treatment revealed its favourable impacts on anticancer immune responses, including suppression of the differentiation into regulatory T cells (Treg), increasing tumour‐infiltrating CD8+ T cells, abolishing the function of MDSCs and so forth.79